Modelling oncogenic Ras/Raf signalling in the mouse

Current Opinion in Genetics and Development

Volumn 19, Issue 1, 2009, Pages 4-11

  Karreth, Florian A ^a,b   Tuveson, David A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

CANCER GROWTH; CARCINOGENESIS; EXPERIMENTAL MOUSE; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FORECASTING; GENES, RAS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

MUS;

EID: 60949110722     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.12.006     Document Type: Review

References (58)

1. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7 (2007) 295-308
2. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4 (2004) 361-370
3. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11-22
5. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002) 6997-7000
6. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
7. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nat Genet 33 (2003) 19-20
8. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-40
9. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 (2007) 645-658
10. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., Campuzano V., and Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4 (2003) 111-120
11. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 (2004) 375-387
12. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., and Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 (2001) 3243-3248
13. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003) 437-450
14. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., and Chodosh L.A. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9 (2007) 493-505. This study provides the first in vivo evidence for the cell biological responses to different expression levels of oncogenic Ras. High levels engaged the p19ARF-p53 tumor suppressor pathway to induce senescence, while low levels promoted hyperplastic growth of mammary epithelial cells.
15. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., and DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 (2003) 3112-3126
16. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., and Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005) 469-483
17. Bardeesy N., Cheng K.H., Berger J.H., Chu G.C., Pahler J., Olson P., Hezel A.F., Horner J., Lauwers G.Y., Hanahan D., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20 (2006) 3130-3146
18. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Fujitani Y., Fujitani S., Wright C.V., and Moses H.L. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20 (2006) 3147-3160
19. Izeradjene K., Combs C., Best M., Gopinathan A., Wagner A., Grady W.M., Deng C.X., Hruban R.H., Adsay N.V., Tuveson D.A., et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11 (2007) 229-243
20. Siveke J.T., Einwachter H., Sipos B., Lubeseder-Martellato C., Kloppel G., and Schmid R.M. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12 (2007) 266-279
21. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., Dubus P., Sandgren E.P., and Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 (2007) 291-302
22. Carriere C., Seeley E.S., Goetze T., Longnecker D.S., and Korc M. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A 104 (2007) 4437-4442
23. Tuveson D.A., Zhu L., Gopinathan A., Willis N.A., Kachatrian L., Grochow R., Pin C.L., Mitin N.Y., Taparowsky E.J., Gimotty P.A., et al. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 66 (2006) 242-247
24. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R.T., and Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
25. Iwanaga K., Yang Y., Raso M.G., Ma L., Hanna A.E., Thilaganathan N., Moghaddam S., Evans C.M., Li H., Cai W.W., et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68 (2008) 1119-1127
26. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., and Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65 (2005) 10280-10288
27. Grady W.M., and Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3 (2002) 101-128
28. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., Jamieson T.J., Guerra C., Ashton G.H., Barbacid M., et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 103 (2006) 14122-14127
29. Calcagno S.R., Li S., Colon M., Kreinest P.A., Thompson E.A., Fields A.P., and Murray N.R. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 122 (2008) 2462-2470
30. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40 (2008) 600-608. Haigis et al. describe oncogene-specific effects in the colon, where K-Ras but not N-Ras induced hyperplasia, suggesting that Ras family members are oncogenic only in cell type-specific contexts.
31. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11 (2005) 63-70
32. Kirsch D.G., Dinulescu D.M., Miller J.B., Grimm J., Santiago P.M., Young N.P., Nielsen G.P., Quade B.J., Chaber C.J., Schultz C.P., et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13 (2007) 992-997
33. Braun B.S., Tuveson D.A., Kong N., Le D.T., Kogan S.C., Rozmus J., Le Beau M.M., Jacks T.E., and Shannon K.M. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 101 (2004) 597-602
34. Chan I.T., Kutok J.L., Williams I.R., Cohen S., Kelly L., Shigematsu H., Johnson L., Akashi K., Tuveson D.A., Jacks T., et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113 (2004) 528-538
35. Chan I.T., Kutok J.L., Williams I.R., Cohen S., Moore S., Shigematsu H., Ley T.J., Akashi K., Le Beau M.M., and Gilliland D.G. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood 108 (2006) 1708-1715
36. Parikh C., Subrahmanyam R., and Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108 (2006) 2349-2357
37. Parikh C., Subrahmanyam R., and Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res 67 (2007) 7139-7146
38. Chin L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon-Cardo C., Horner II J.W., and DePinho R.A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11 (1997) 2822-2834
39. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., and Taketo M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64 (2004) 48-54
40. G12V germline mouse model, which did not develop cancer but displayed phenotypes resembling human Costello syndrome.
41. ••]
42. ••] describe the generation of conditional oncogenic B-Raf mutant mice. Upon activation by Cre in the appropriate cell type, these mice developed haematopoietic and pulmonary malignancies.
43. Collier L.S., Carlson C.M., Ravimohan S., Dupuy A.J., and Largaespada D.A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436 (2005) 272-276
44. Kerkhoff E., Fedorov L.M., Siefken R., Walter A.O., Papadopoulos T., and Rapp U.R. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Diff 11 (2000) 185-190
45. Ceteci F., Ceteci S., Karreman C., Kramer B.W., Asan E., Gotz R., and Rapp U.R. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 12 (2007) 145-159
46. Lyustikman Y., Momota H., Pao W., and Holland E.C. Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 10 (2008) 501-510
47. Le L.Q., and Parada L.F. Tumor microenvironment and neurofibromatosis type I. connecting the GAPs. Oncogene 26 (2007) 4609-4616
48. Rubin J.B., and Gutmann D.H. Neurofibromatosis type 1 - a model for nervous system tumour formation?. Nat Rev Cancer 5 (2005) 557-564
49. Cabrita M.A., and Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 11 (2008) 53-62
50. Shaw A.T., Meissner A., Dowdle J.A., Crowley D., Magendantz M., Ouyang C., Parisi T., Rajagopal J., Blank L.J., Bronson R.T., et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21 (2007) 694-707
51. Salojin K., and Oravecz T. Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes. J Leukoc Biol 81 (2007) 860-869
52. ••]
53. ••]
54. ••]
55. G12D-driven tumorigenesis was impaired, while loss of Rce1 enhanced tumorigenicity.
56. •]
57. •]
58. •] showed the importance of different Ras effector pathways for Ras-mediated tumorigenesis, distinguishing these pathways as relevant therapeutic targets.